In conclusion, carvedilol prevents B(a)P-induced lung toxicity, inflammation and carcinogenesis via targeting multiple oncogenic signaling pathways, including MAPK, AhR and NF-κB, and, therefore, represents a promising drug candidate for use in lung cancer chemoprevention. Here, NFKB1 is linked to lung carcinoma.